(AOF) – Nicox announced that the United States Patent and Trademark Office (USPTO) has decided that the American patent covering latanoprostene bunod marketed by Bausch + Lomb under the brand Vyzulta is eligible for an extension of its term of protection for a period of 5 years. The company also requested an extension of the term of protection for two other US patents covering latanoprostene bunod. Nicox and Bausch + Lomb must now select which of these patents will be subject to the term extension.
“We are reaching the final step in the process of extending the patent exclusivity period for latanoprostene bunod which would guarantee royalty payments to Nicox on sales of Vyzulta until at least 2029,” said Gavin Spencer, chief business officer. officer of Nicox. “The majority of the company’s revenue from licensing agreements currently comes from Vyzulta, and amounted to €4.2 million in 2023, representing an annual increase of 29%,” he said. He specifies.
AOF – LEARN MORE
Learn more about the Pharmacy sector
Oncology, priority of pharmaceutical giants
Sanofi’s stock market disappointment recorded at the end of October 2023 underlines the new direction for the group, which has now set oncology as its number 1 priority. Efforts in this segment, where therapies are advancing the fastest, notably involve investments in R&D which weigh on profitability. Sanofi therefore announced a drop in its earnings per share in 2024 and the abandonment of its objective of an operating margin of 32% in 2025. Merck has just unveiled a new alliance. It will pay up to $22 billion to the Japanese group Daiichi Sankyo as part of a partnership on experimental cancer treatments. While some experts estimate that the United States represents nearly half of global oncology spending (drugs and treatments), or $196 billion in 2022, Chinese spending in this area has more than doubled in five years, going from 5 to 11.8 billion dollars.